-
Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial
•
Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its aldosterone synthase inhibitor (ASi) BI 690517, used alone or in combination with the antidiabetic Jardiance (empagliflozin), in patients with chronic kidney disease (CKD), with or without type 2 diabetes (T2D). The trial aimed to evaluate…
-
Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery
•
China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic partnership with Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) at the 6th China International Import Expo (CIIE) in Shanghai. The collaboration focuses on the science research, application, and translation of metaverse visualization surgery,…
-
Danone Enters China’s Adult FSMP Market with Local Production of Fortimel
•
France-based food company Danone has revealed its strategic plans to enter the adult foods for special medical purposes (aFSMP) category in China. This move marks a significant expansion for the firm, which intends to manufacture its products locally, beginning with the launch of Fortimel, a high-protein, high-energy oral nutritional supplement…
-
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
•
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with the Italy-headquartered Menarini Group. This agreement grants SciClone exclusive development and commercialization rights to Menarini’s Orserdu (elacestrant) in China. SciClone will be responsible for conducting clinical trials, regulatory filings, and marketing and distribution of Orserdu…
-
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
•
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its human papillomavirus (HPV) associated tumor therapeutic mRNA vaccine, RG002. This marks a significant step forward in the development of the vaccine,…
-
Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China
•
The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), is set for priority review status in China. This priority review is specifically for the ADC’s potential use as a…
-
Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA
•
Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay…
-
Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China
•
At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a partnership with China-based New Horizon Health Technology Co., Ltd (HKG: 6606), a leading cancer diagnostics developer. The collaboration aims to develop a comprehensive management solution for Helicobacter pylori patients in China, underscoring Takeda’s (TYO: 4502)…
